Emster Kurt von - 29 Sep 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 29 Sep 2023
Net transaction value: -$170,070
SEC form: 4
Accepted by SEC: 29 Sep 2023, 17:54:02 UTC
Prior SEC filing: 08 Jun 2023
Next SEC filing: 26 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Paul Quinlan, as attorney-in-fact for Kurt von Emster

Key filing fact

Emster Kurt von filed Form 4 for CymaBay Therapeutics, Inc. on 29 Sep 2023.

Key facts

This page summarizes Emster Kurt von's Form 4 filing for CymaBay Therapeutics, Inc..
6 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 29 Sep 2023, 17:54.

Change

Previous filing in this sequence was filed on 08 Jun 2023.
Current net transaction value: -$170,070.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CBAY transaction

Common Stock

Options Exercise

Transaction value: $79,605
Shares: +15,921
Change %: +18%
Price: $5.00
Shares after: 105,921
Date: 29 Sep 2023
Ownership: Direct

CBAY transaction

Common Stock

Sale

Transaction value: $249,675
Shares: -15,921
Change %: -15%
Price: $15.68
Shares after: 90,000
Date: 29 Sep 2023
Ownership: Direct
Footnotes: F1, F2

CBAY holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 18,406
Date: 29 Sep 2023
Ownership: By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CBAY transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -6,357
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 29 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,357
Exercise price: $5.00
Footnotes: F4

CBAY transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -943
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 29 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 943
Exercise price: $5.00
Footnotes: F5

CBAY transaction Derivative

Stock Appreciation Right

Options Exercise

Transaction value: $0
Shares: -3,372
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 29 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,372
Exercise price: $5.00
Footnotes: F6

CBAY transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -5,249
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 29 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,249
Exercise price: $5.00
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 30, 2023.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.54 to $15.89, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

This corrects a typographical error made in the reporting person's previous Form 4 filings. In filings between October 2, 2017 and March 17, 2018 (inclusive) the reporting person reported 17,236 shares held indirectly rather than the 17,326 shares that the reporting person actually held indirectly (and had reported previously). After adding 1,080 shares on June 5, 2018 the reporting person incorrectly reported in a filing on June 7, 2018 and in filings thereafter owning 18,316 shares indirectly rather than the 18,406 shares that the reporting person actually held indirectly.

Footnote F4

The option vested as to 1/3 of the underlying shares on October 31, 2013 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.

Footnote F5

The option vested as to 1/4 of the underlying shares on April 2, 2010 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.

Footnote F6

The incentive award (the "Award") was granted under the CymaBay 2013 Equity Incentive Plan and could be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The shares subject to the Award vested in 48 equal monthly installments from the grant date.

Footnote F7

The option vested as to 1/3 of the underlying shares on January 6, 2014 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.